GlassScriptPhysician profile
Daniel J Heine
NPI 1730317918
$4,261.07
in general payments reported to CMS, 2019-2025
24 companies · $625 in 2025
The $625 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $253 · 2021: $617 · 2022: $844 · 2023: $761 · 2024: $703 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Long Term Medical Supply Or Device Loan: $27.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.51 |
| Long Term Medical Supply Or Device Loan | $27.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $926.57 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $539.06 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $442.88 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $420.38 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $398.00 | 2019-2022 | |
| Sanofi Pasteur INC. | $224.57 | 2021-2025 | |
| Cranial Technologies, INC | $186.55 | 2019-2025 | Doc Band |
| Neos Therapeutics, LP | $178.59 | 2019-2024 | Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $145.80 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $114.45 | 2019-2025 | Gardasil 9, Enflonsia, Vaxelis |
| Pfizer INC. | $106.91 | 2019-2025 | |
| Seqirus USA INC | $96.27 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Abbott Laboratories | $74.25 | 2019 | |
| Glaxosmithkline, LLC. | $68.06 | 2020-2023 | Bexsero |
| Adlon Therapeutics L.P. | $61.80 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $43.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $41.47 | 2024-2025 | |
| Kaleo, INC. | $40.52 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $38.56 | 2021-2023 | |
| Biofire Diagnostics, LLC | $27.67 | 2019 | |
| Baxter Healthcare | $27.43 | 2024 | Hillrom - Audioscope 3 |
| Teva Pharmaceuticals USA, INC. | $20.69 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $19.78 | 2025 | Neffy |
| Noven Therapeutics, LLC | $17.23 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Heine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.